Motixafortide is a peptide inhibitor of CXCR4 used to mobilize hematopoietic stem cells prior to collection and autologous transplantation in multiple myeloma patients. Hematopoietic stem cell transplantation (HSCT) is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's own stem cells (i.e....
- Mechanism
- Curator reviewed · 2 references
Motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4) that blocks the binding of its ligand, stromal-derived factor-1α (SDF-1α)/C-X-C Motif Chemokine Ligand 12 (CXCL12). Both CXCR4 and SDF-1α play a role in the trafficking of hematopoietic stem cells to the bone marrow compartment, with CXCR4 helping to anchor stem cells to the marrow matrix (via SDF-1α or the induction of other adhesion molecules). The inhibition of CXCR4 thus results in elevations in circulating hematopoietic stem and progenitor cells into the peripheral circulation, facilitating their collection for the purposes of autologous transplantation.
- Primary indication
- Motixafortide is indicated for use in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.Curator reviewed · 1 structured indication
- Formula / weight
- C97H144FN33O19S2 · 2159.6 Da
- First approval
- United States, 2023
- Code names
- 4F-benzoyl-TN-14003 · BKT-140 · BL-8040
- Brand names
Resolves to
What you can answer from here — as of September 13, 2026
Which drugs share a target with Motixafortide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account